Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia-Reference-Cited by-同舟云学术

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Published:2013-07-04 Issue:1 Volume:369 Page:32-42
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Byrd John C.,Furman Richard R.,Coutre Steven E.,Flinn Ian W.,Burger Jan A.,Blum Kristie A.,Grant Barbara,Sharman Jeff P.,Coleman Morton,Wierda William G.,Jones Jeffrey A.,Zhao Weiqiang,Heerema Nyla A.,Johnson Amy J.,Sukbuntherng Juthamas,Chang Betty Y.,Clow Fong,Hedrick Eric,Buggy Joseph J.,James Danelle F.,O'Brien Susan

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215637

Cited by 1993 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conserved gatekeeper methionine regulates the binding and access of kinase inhibitors to ATP sites of MAP2K1, 4, and 7: Clues for developing selective inhibitors;Bioorganic & Medicinal Chemistry Letters;2024-11

2. Targeting EGFR by Newer 1-(3,5-Bis((E)-4‑hydroxy-3-methoxystyryl)-1H-pyrazol-1-yl)-2-((substituted phenyl)amino)ethan-1-one Analogues for the Treatment of Cancer: Synthesis, In-vitro and In-silico Studies;Journal of Molecular Structure;2024-11

3. Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial;Annals of Hematology;2024-09-14

4. A novel class of potent antiangiogenic and antioxidant pyrazoles: synthesis, bioactivity, docking and ADMET studies;Future Medicinal Chemistry;2024-09-12

5. Utilizing risk factors to guide treatment decisions in chronic lymphocytic leukemia;Expert Review of Anticancer Therapy;2024-09-02